NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
It is a naturally occurring substance in humans and organisms. Judging from the fact that breast milk contains NMN, it can be said to be one of the nutrients that humans ingest at the beginning of life. Yellow and green vegetables also contain NMN, so it is different from medicine. NMN is a food of natural origin and is safe.
Introduction On Feb 25-29, 2024, BONTAC was invited to 2024 Boao Healthy Food Science Conference & Exposition (FHE 2024) and made a discussion with the industry elites on the innovation of science and technology as well as the trend towards industry development in the health food area. Conference profile There are 15 academicians, 300 report experts, and over 2000 delegates from around the world gathering around the conference. More than 40 professional forums are planned in FHE 2024, attracting the active participation of domestic and foreign industry leaders such as Danone, Nestle and Pepsi. BONTAC star products in FHE 2024 By dirt of its innovative technology and strong R&D strength in the field of green biosynthesis, BONTAC stands out from the crowd. To date, there are over 170 global patents by BONTAC. BONTAC star products, including NMN, NADH and ginsenoside Rh2/Rg3, are present in FHE 2024, which are highly recognized by many brand owners. Many attendees are attracted to learn more and negotiate with BONTAC for further cooperation. Notably, Professor Chen Junshi from Chinese Academy of Engineering visited the booth of BONTAC, gave guidance to the team of BONTAC and highly praised the innovative achievements in the field of biosynthesis. Facilitating the development of high-quality health food via innovation of science and technology From the traditional healthcare with herbs to modern precision nutrition, health has always been the focus of people. With the progress of science and technology, the development of new functional nutrients has gradually relied on the support of technical innovation. In various niche areas of health, NMN has emerged as an essential force in health industry by leverage of its unique science base and broad application prospect. Mounting scientific research and clinical practice have attested the obvious efficacy of NMN in promoting the immunity, improving the cardiovascular health, and alleviating the fatigue. Conclusion FHE 2024 is the first domestic platform for the communication of scientific evidence on health beneficial food. In the future, BONTAC will continue to provide comprehensive solutions for anti-aging series products including coenzyme and natural extracts, and facilitate the development of high-quality food via innovation of science and technology. About BONTAC BONTAC has been dedicated to the green biosynthesis for 12 years, with the intention of creating a better life for human beings. Up till now, there are 173 patents by BONTAC. As the pioneer of NMN industry, BONTAC is the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”.
Introduction It has been reported that infection with Gram-negative bacteria can disrupt the osteogenic differentiation. Notably, nicotinamide mononucleotide (NMN) protects against osteogenesis from inflammation caused by Gram-negative bacterial infections possibly via regulating the Wnt/β-catenin signaling pathway. About osteogenic differentiation Osteogenic differentiation refers to the formation process of osteoblasts from bone marrow mesenchymal stem/stromal (a.k.a. skeletal stem) cells and bone progenitor cells, which is a key event in bone formation during development, fracture repair, and tissue maintenance. Abnormalities in the process of osteogenic differentiation may disrupt physiological bone homeostasis, which is strongly associated with a variety of bone-related diseases such as osteoporosis, bone tumors, and osteoarthritis, making negative impacts upon fracture healing and repair of bone tissue defects. LPS-induced suppression of osteogenesis Lipopolysaccharide (LPS) is a component of the cell wall in Gram-negative bacteria, which is intensively applied to mimic Gram-negative bacterial infections in cell and animal models. LPS can hamper osteogenic differentiation of pre-osteoblasts MC3T3-E1 by diminishing the expression of mRNA markers (Alp1, Bglap, Runx2, and Sp7), ALP activity, and mineralization. Partial protection of NMN against the LPS-induced suppression of osteogenesis LPS-induced inhibition of osteogenic differentiation in MC3T3-E1 cells is partially offset by 1 mM of NMN. Concretely, the mRNA levels of Alp1, Bglap, and Sp7 in cells co-treated with NMN and LPS are relatively higher than those in cells treated solely with LPS. Furthermore, ALP activity and mineralization repressed by LPS are restored in the presence of NMN (1 mM). Potential involvement of the Wnt/β-catenin signaling pathway in NMN's effect on osteogenesis Wnt/β-catenin signaling pathway has been attested to play a vital role in osteogenesis by promoting bone formation and inhibiting bone resorption. In cells treated with LPS, β-catenin is localized in the cytoplasm rather than the nucleus. Following NMN treatment, β-catenin is translocated to the nucleus, similar to what occurred in response to the treatment of osteogenic induction medium (OIM). Meanwhile, the fluorescence intensity of β-catenin is restored upon NMN treatment. Conclusion NMN has a protective role against LPS-induced osteogenesis disruption, which is potentially achieved by the Wnt/β-catenin signaling pathway. NMN may function as a viable therapeutic strategy to preserve bone homeostasis in elderly and immunocompromised patients. Reference Kang I, Koo M, Jun JH, Lee J. Effect of nicotinamide mononucleotide on osteogenesis in MC3T3-E1 cells against inflammation-induced by lipopolysaccharide. Clin Exp Reprod Med. Published online April 11, 2024. doi:10.5653/cerm.2023.06744 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction Ginsenoside Rg3 (Rg3) holds great promise as a potential drug for preventing scar formation, but it is often difficult for it to work alone due to its poor water solubility and low bioavailability. Herein, a novel Rg3-loaded dermal extracellular matrix (DECM) hydrogel scaffolds are prepared via 3D printing and nanoloading technologies, which improves the biosafety profile of Rg3 to a large extent, maintains a consistent local drug concentration for an extended duration and prolongs therapeutic effects, realizing the final goal of scar-free healing. The merits of 3D-printed DECM hydrogel scaffolds loaded with Rg3 3D-printed DECM hydrogel scaffolds have good supportability and stability. They could be folded into different shapes without obvious deformation or breakage, closely resembling the properties of natural skin. The continuous porous structure of DECM-2MSN scaffolds enables the faster transport of nutrients, oxygen, water, and metabolic wastes within the platform, which facilitates the wound healing. The uniqueness of 3D-printed DECM hydrogel scaffolds loaded with Rg3 Through decellularization, about 98.57% of dsDNA is removed from DECM, leaving few cellular remnants while preserving collagen in DECM, which simulates the natural extracellular matrix microenvironment for skin defect healing to the greatest extent, reducing the risk of immune rejection. Hydrogel exhibits excellent biocompatibility and solid-like rheological properties. Furthermore, mesoporous silica nanoparticles (MSNs) are introduced into the system to encase the Rg3 to control its release rate and enhance its bioavailability. The role of Rg3-loaded hydrogel scaffolds in wound healing The wound in DECM-2MSNs/Rg3 group has completely healed, exhibiting smooth and uniform regenerated epithelium with clear boundaries between the epidermis and dermis. During the wound healing process, Rg3 can suppress the excessive inflammation, hinder the formation of blood vessels, and prevent excessive and disordered proliferation of granulation tissue at the wound site, as manifested by the low expression of CD31, VEGF and TGF-β levels in DECM-2MSNs/Rg3 group. In the later stages of wound healing, Rg3 could repress collagen accumulation, thereby impeding scarring, without affecting the normal healing of the wound. Conclusion Rg3-loaded hydrogel scaffold can inhibit wound inflammation and collagen accumulation to repress scar formation. By integrating 3D bioprinting and nanoloading technologies to prepare this innovative wound dressing, the efficacy of Rg3 has been greatly improved, providing a novel therapeutic approach for scar-free wound healing. Reference Wang X, Wei P, Hu C, Zeng H, Fan Z. 3D printing of Rg3-loaded hydrogel scaffolds: anti-inflammatory and scar-formation related collagen inhibitory effects for scar-free wound healing. J Mater Chem B. Published online April 22, 2024. doi:10.1039/d3tb02941g BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). One-stop service for customized product solution is available in BONTAC. With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.